A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
Phase 3
45 Years
N/A
45 Years
N/A
Not Enrolling
Female
Quality of Life
Female
Quality of Life
Trial Information
A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
Inclusion Criteria:
- Eligible for entry into the main ATAC trial 1033IL/0029
- Completion of a baseline questionnaire
Exclusion Criteria:
- Excluded from entry into the main ATAC trial (1033IL/0029)
- If, in the investigators opinion, the patient would be unable to comply with this
sub-protocol due to psychiatric or literacy reasons
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Outcome Measure:
Time to withdrawal
Safety Issue:
No
Authority:
Australia: Department of Health and Ageing Therapeutic Goods Administration
Study ID:
1033IE/0029
NCT ID:
NCT00784680
Start Date:
April 1998
Completion Date:
April 2004
Related Keywords:
- Quality of Life
Name | Location |
|---|
